HBOT Conversations:
Dr. Paul Harch & Autism
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Autism is the seventh in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 7 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch about Autism.
The percentage of children with Autism is increasing at an alarming rate. In order to successfully treat Autism and navigate around the roadblocks, Dr. Harch explains that it’s important to understand that Autism is not a psychiatric diagnosis. Autism is a wounding condition of the brain, without all of the potential contributors being identified to the wounding process.
Dr. Harch was the first to treat a series of children with Autism using Hyperbaric Oxygen Therapy; a therapy which in and of itself is neuroplastic (it is a neuroplast — affecting neuroplasticity). He states that there’s a plethora of information on the fact that Autism is a physical brain abnormality, and that’s what’s causing this Autism phenomenon. Functional imaging scans that have been done on these Autistic children shows 90% of them have a problem involving primarily the temporal lobes and frontal lobes; mostly temporal lobes. Dr. Harch has treated a good series of these children with Hyperbaric Oxygen Therapy and about 80% of them will respond to the treatment. There are various causes, which may explain why 100% don’t respond to HBOT, since there are different insults to the brains and/or it’s environmental. But, Dr. Harch stresses that there’s no such thing as a genetic epidemic, so this Autism epidemic we’re seeing must either be caused by environmental factors or infectious agents.
Dr. Harch affirms that the underlying nature of Autism is that there’s a dominant immune dysfunction in these children that often manifests in the GI tract, but also in the brain. Dr. Harch recommends our viewers read this beautiful article by Dr. Dan Rossignol, a Family Practice Physician with two autistic sons. In the article Dr. Rossignol reviews all of the pathophysiology — the disease processes — that have been identified in Autistic children, and he reviews all of the science of Hyperbaric Oxygen Therapy and the effect it has on all of those disease processes. In the end, HBOT is shown to be a good match for the treatment of Autism.
di Girolamo asks Dr. Harch if Autism appears to be an inflammatory issue, with Dr. Harch agreeing that it does seem to appear that way. Dr. Harch went on to explain that of the 8,1001 genes that have been shown to be affected in human cells by a single Hyperbaric Oxygen exposure, the largest clusters involved are the anti-inflammatory genes — upregulation is turned on and there’s suppression of the pro-inflammatory genes. Plus, there are many genes that are activated within the immune system which also supports the use of HBOT for the treatment of Autism as a dominant immune dysfunction.
The studies have been controversial and complicated on Hyperbaric Oxygen Therapy for Autism. But contrary to the results of these studies, Dr. Harch is here to say that the proof is in the imaging. He has imaging revealing that after only one treatment — sometimes it’s a series of treatments — changes are seen in these children’s brains, and there’s improvement in profusion (such as in the temporal lobes).
Dr. Harch professes that what he’s been trying to do all these years, these decades, is to answer a simple question, “Does Hyperbaric Oxygen Therapy work for your condition or not?” He explains it’s critical to start with HBOT solely and not throw a bunch of other therapies into the mix because then you have too many variables, and you won’t know exactly what’s helping and what’s not. He explains Hyperbaric Oxygen Therapy is a foundation biological therapy, and declares there is no identified therapy out there that can do what Hyperbaric Oxygen can do; including activating 40% of our genome. There’s nothing.
Dr. Harch references Chapter 12 of his book, The Oxygen Revolution, and says “I’m sorry but if your doctor is giving you negative information, flatly ignore him! Go get this therapy for your child!” Treating with HBOT is no different than if you dosed the child with a drug, or a drug combination. This is a two component drug we’re dosing with that’s safe and effective — pressure and oxygen. We encourage you to try it, because it could change your life if you or your child are a part of this 80% success rate.
Subscribe Now, It’s Free!
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
The wound/burn guidelines – 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene.
Abstract: We aimed to prepare guidelines for the management of diabetic ulcer/gangrene with emphasis on the diagnosis and treatment of skin symptoms. They serve as a tool to improve the quality of the diagnosis and treatment in each patient and, further, to improve...
Clinical Trial – HBOT Global Functioning After Stroke
Stroke is one of the leading causes of disability and death in North America and Europe. Up
to 30% of stroke survivors never recuperate completely and suffer from loss of function and
poor quality of life. To improve recovery after stroke, innovative interventions should be a
priority.
Hyperbaric oxygen therapy (HBOT) is an intermittent inhalation of 100% oxygen in a hyperbaric
chamber at a pressure higher than 1 absolute atmosphere (ATA). There is a growing body of
evidence that HBOT can enhance ability of brain to changes its structure (neuroplasticity) in
order to recover. Exercise program during HBOT can augment the effect. Although, recent
randomized controlled trials in patients with chronic brain injury showed promising results,
there are no studies demonstrating combine effect HBOT and exercise rehabilitation program on
stroke recovery.
The proposed study investigates feasibility, safety and efficacy of using a combination of
HBOT and exercise program to improve arm function recovery in chronic stroke patients. In
this pilot randomized control trial, investigators will compare the combination of HBOT and
the focused rehabilitation exercise program versus exercise program alone on recovery of arm
function in patients with chronic stroke.
Clinical Trial – Hyperbaric Oxygen Therapy and Acute Kidney Injury
Kidney injury is a serious complication of cardiac surgery that occurs in up to 30% of
patients and increases the risk of adverse outcomes. Kidney injury initiates when oxygen
supply to the kidney drops below levels that are needed for normal cellular function, causing
tissue oxygen deficiency (hypoxia), activation of the inflammatory cascade, and oxidative
stress. Together, these events further impair tissue oxygenation, culminating in impaired
kidney function due to cellular injury and death.
There are no effective therapies for kidney injury after cardiac surgery, but there is
evidence that recovery is possible if the processes of injury – i.e., impaired oxygen
delivery, increased inflammatory response, and oxidative stress – are ameliorated soon after
the onset of injury. Hyperbaric oxygen therapy (HBOT) – which entails the intermittent
inhalation of 100% oxygen in a hyperbaric chamber at a pressure higher than one absolute
atmosphere (> 760 mmHg) – has been shown to positively affect all of these processes (i.e.,
to improve tissue oxygenation, reduce inflammation, and reduce oxidative stress). Thus, we
hypothesized that HBOT will reduce the severity of kidney injury after cardiac surgery if it
is initiated soon after onset of injury. This hypothesis has not been tested in humans, but
is supported by animal studies.
In this first-in-human, unblinded, controlled pilot trial, 20 adult patients who develop
severe kidney injury soon after cardiac surgery will be randomized (after obtaining informed
consent from the patient or surrogate) to standard-of-care or early HBOT. Severe kidney
injury will be defined as a ≥30% drop in kidney function within 6 hours of surgery (as
determined by change in creatinine from before surgery to Intensive Care Unit (ICU)
admission). This degree of injury occurs in ~ 2% of patients and is associated with a 12-fold
increase in the risk of complete kidney failure (requiring dialysis) or death. Patients will
be excluded if they have any relative or absolute contraindications to HBOT (e.g., severe
ventricular dysfunction, ventricular assist device, severe respiratory dysfunction,
pneumothorax, bronchospasm).